|
|
Nanoagents for Cancer TheragnosisVivek Takare, Marta Bolsa, Vladimir Ivošev, and Vu-Long Tran The 'Nanoagents' team is comprised of experimentalists from chemistry, biology, and medical physics. Our goal is to design, synthesize, and characterize the next generation of nanoparticles as radiosensitizers and diagnostic tools. We also study their fate inside the cellular environment and the cell damage caused by the combination of nanoparticles and different radiation beams. We are approaching novel solutions to improve cancer radiotherapy in terms of not only efficacy but also safety. |
|
|
Pre-clinical EvaluationAli Traore, Dária Boscolo, Alexey Verkhovtsev, and Soraia Rosa The 'Preclinical Evaluation' team combines their efforts to understand better how nanoscale processes initiated by the interaction of radiation with living matter affect biological responses, establishing a link between nanoscale interaction and clinical effects. Combining advanced experimental, theoretical, and modeling tools, the team investigates nanoscale interactions for preclinical testing in cell-based models and explores their clinical applicability. The major goal of this team in ARGENT is to evaluate the use of the new methods and tools developed in the project for better patient outcomes. |
|
|
NanodosimetryPablo de Vera, Sophie Grellet, Arkadiusz Mika, Lilian Ellis-Gibbings, and Kaspar Haume The 'Nanodosimetry' team combines experiments and simulation to answer the most fundamental questions regarding the mechanisms present in radiation-induced damage in cells. They study biomolecules, nanoagents, and their mutual interactions in the presence of fast and slow charged particles. This approach is crucial for the optimization of both the interaction of new nano-radio-sensitizers with radiotherapy and the treatment protocols that take them into account. |
